Table 1.
Patient characteristics
| Clinicopathologic characteristics |
All patients n (%) |
CD147 high expression n (%), χ2, P |
MMP-9 high expression n (%), χ2, P |
|---|---|---|---|
| Patient included | 127 (100.0) | 61 (48.0) | 68 (53.5) |
| Age (median age) | 49 (30–68) | 47 (30–66) | 54 (31–68) |
| Lymph node | |||
| 0 | 71 (55.9) | 21 (34.4) 21.97 0.000 | 20 (29.4) 41.68 0.000 |
| ≥1 | 56 (44.1) | 40 (65.6) | 48 (70.6) |
| Histology grade | |||
| 1/2 | 48 (49.0) | 24 (39.3) 6.002 0.014 | 27 (39.7) 7.645 0.006 |
| 3 | 50 (51.0) | 37 (60.7) | 41 (60.3) |
| Tumor size | |||
| ≤2 | 59 (46.5) | 21 (34.4) 6.830 0.009 | 24 (35.3) 7.332 0.007 |
| >2 | 68 (53.5) | 40 (65.6) | 44 (64.7) |
| Pathological stage | |||
| I + II | 45 (35.3) | 16 (26.2) 4.346 0.037 | 16 (23.5) 9.066 0.003 |
| III | 82 (64.5) | 45 (73.8) | 52 (76.5) |
| P53 | |||
| Negative | 57 (44.9) | 28 (45.9) 0.049 0.824 | 29 (42.6) 0.296 0.587 |
| Positive | 70 (55.1) | 33 (54.1) | 39 (57.4) |
| Ki67 | |||
| ≤30 % | 39 (30.7) | 11 (18.0) 8.864 0.003 | 17 (25.0) 7.046 0.008 |
| >30 % | 88 (69.3) | 50 (82.0) | 51 (75.0) |
| Chemotherapy regimen | |||
| Taxanes | 35 (27.6) | 20 (32.8) 3.363 0.186 | 25 (36.7) 7.393 0.125 |
| Anthracycline | 23 (18.1) | 13 (21.3) | 13 (19.1) |
| Anthracycline + taxanes | 69 (54.3) | 28 (45.9) | 30 (44.1) |
| Menopausal status | |||
| Pre-menopausal | 67 (52.7) | 27 (44.3) 3.397 0.065 | 36 (52.9) 0.002 0.964 |
| Postmenopausal | 60 (47.3) | 34 (55.7) | 32 (47.1) |
| Serum CA 15-3 levels | |||
| Positive | 31 (24.4) | 16 (26.2) 0.211 0.646 | 20 (29.4) 1.985 0.159 |
| Negative | 96 (75.6) | 45 (73.8) | 48 (70.6) |
| Serum CEA levels | |||
| Positive | 38 (29.9) | 18 (29.5) 0.010 0.922 | 24 (35.3) 2.015 0.156 |
| Negative | 89 (70.1) | 43 (70.5) | 44 (64.7) |